» Articles » PMID: 37013458

Effects of 3-HAA on HCC by Regulating the Heterogeneous Macrophages-A ScRNA-Seq Analysis

Overview
Journal Adv Sci (Weinh)
Date 2023 Apr 4
PMID 37013458
Authors
Affiliations
Soon will be listed here.
Abstract

Kynurenine derivative 3-hydroxyanthranilic acid (3-HAA) is known to regulate the immune system and exhibit anti-inflammatory activity by inhibiting T-cell cytokine secretion and influencing macrophage activity. However, the definite role of 3-HAA in the immunomodulation of hepatocellular carcinoma (HCC) is largely unexplored. An orthotopic HCC model and treated with 3-HAA by intraperitoneal injection is developed. Furthermore, cytometry by time-of-flight (CyTOF) and single-cell RNA sequencing (scRNA-seq) analyses are carried out to define the immune landscape of HCC. It is found that 3-HAA treatment can significantly suppress tumor growth in the HCC model and alter the level of various cytokines in plasma. CyTOF data shows that 3-HAA significantly increases the percentage of F4/80 CX3CR1 Ki67 MHCII macrophages and decreases the percentage of F4/80 CD64 PD-L1 macrophages. scRNA-seq analyses demonstrate that 3-HAA treatment is proved to regulate the function of M1 macrophages, M2 macrophages, and proliferating macrophages. Notably, 3-HAA inhibits the proinflammatory factors TNF and IL-6 in multiple cell subsets, including resident macrophages, proliferating macrophages, and pDCs. This study reveals the landscape of immune cell subsets in HCC in response to 3-HAA, indicating that 3-HAA may be a promising therapeutic target for HCC.

Citing Articles

Aromatic Amino Acid Metabolites: Molecular Messengers Bridging Immune-Microbiota Communication.

Shin H, Bang Y Immune Netw. 2025; 25(1):e10.

PMID: 40078785 PMC: 11896664. DOI: 10.4110/in.2025.25.e10.


Role of Kynurenine and Its Derivatives in Liver Diseases: Recent Advances and Future Clinical Perspectives.

Tan Q, Deng S, Xiong L Int J Mol Sci. 2025; 26(3).

PMID: 39940736 PMC: 11816720. DOI: 10.3390/ijms26030968.


3-Hydroxyanthranic acid inhibits growth of oral squamous carcinoma cells through growth arrest and DNA damage inducible alpha.

Gan G, Zhou X, Zheng Q, Gao X, Chen X, Zhang H Transl Oncol. 2025; 52:102278.

PMID: 39799750 PMC: 11770551. DOI: 10.1016/j.tranon.2025.102278.


Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.


Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.

Sun Y, Zhang H, Li Y, Zhou C, Han J Front Immunol. 2024; 15:1450525.

PMID: 39439786 PMC: 11493604. DOI: 10.3389/fimmu.2024.1450525.


References
1.
Li L, Wang T, Li S, Chen Z, Wu J, Cao W . TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway. Front Oncol. 2021; 10:562823. PMC: 7851084. DOI: 10.3389/fonc.2020.562823. View

2.
Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A . T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9(10):1069-77. DOI: 10.1038/sj.cdd.4401073. View

3.
Xue C, Jia J, Gu X, Zhou L, Lu J, Zheng Q . Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma. Signal Transduct Target Ther. 2022; 7(1):335. PMC: 9515207. DOI: 10.1038/s41392-022-01159-9. View

4.
Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L . The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases. Theranostics. 2021; 11(12):6006-6018. PMC: 8058709. DOI: 10.7150/thno.59841. View

5.
De Falco A, Caruso F, Su X, Iavarone A, Ceccarelli M . A variational algorithm to detect the clonal copy number substructure of tumors from scRNA-seq data. Nat Commun. 2023; 14(1):1074. PMC: 9968345. DOI: 10.1038/s41467-023-36790-9. View